Clinical review report: Dolutegravir/Rilpivirine (Juluca) (ViiV healthcare)
The objective of this systematic review was to evaluate the beneficial and harmful effects of Juluca, a fixed-dose combination of dolutegravir (an INSTI) plus rilpivirine (an NNRTI), as a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults wh...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, June 2018
|
| Edition: | Final clinical review report (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this systematic review was to evaluate the beneficial and harmful effects of Juluca, a fixed-dose combination of dolutegravir (an INSTI) plus rilpivirine (an NNRTI), as a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults who are virologically stable and suppressed (HIV-1 RNA < 50 copies/mL) |
|---|---|
| Physical Description: | 1 PDF file (74 pages) illustrations |